Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of JNJ-78278343 in Advanced Prostate Cancer
jRCT2031240484Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of pasritamig in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with adverse events (AEs), Number of participants with AEs by severity and 1 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
pasritamig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031240484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240484.